Table 3.
Prior surgery, radiotherapy and chemotherapy of the patients
| Characteristic | n (%) | |
|---|---|---|
| Primary breast surgerya | ||
| Axillary lymphnodectomy | 1,809 (20.3) | |
| BCS | 3,377 (38.0) | |
| Mastectomy | 1,062(11.9) | |
| Oncoplastic surgery | 191 (2.2) | |
| No surgery | 2 (< 0.1) | |
| Other | 65 (0.8) | |
| Sentinel lymph node biopsy | 2,393 (26.9) | |
| Neoadjuvant chemotherapy (n = 4,397) | ||
| Anthracycline-containing therapy | 42 (1.0) | |
| Anthracycline- and taxane-containing therapy | 225 (5.1) | |
| No chemotherapy scheduled | 4,112 (93.5) | |
| Other | 18 (0.4) | |
| Post-operative chemotherapy (n = 4,397) | ||
| Not scheduled | 2,715 (61.8) | |
| Scheduled | 1,682 (38.3) | |
| Completed | 1,440 (32.8) | |
| In progress/not started | 99 (2.3) | |
| Not disclosed | 143 (3.3) | |
| Scheduled post-operative chemotherapy regimens (n = 1,682) | ||
| Anthracycline-containing therapy | 610 (36.3) | |
| Anthracycline- and taxane-containing therapy | 943 (56.1) | |
| CMF | 20 (1.2) | |
| Other therapy | 109 (6.5) | |
| Post-operative radiotherapy (n = 4,397) | ||
| Not scheduled | 646 (14.7) | |
| Scheduled | 3,751 (85.3) | |
| Completed | 837 (19.0) | |
| In progress/not started | 2,519 (57.3) | |
| Not disclosed | 395 (9.0) | |
| Post-operative radiotherapy according to surgery (n = 4,333) | BCS (n = 3,301)b | Mastectomy (n = 1,032)b |
| Not scheduled | 163 (4.9) | 484 (46.9) |
| Scheduled | 3,138 (95.1) | 548 (53.1) |
a
Total number of procedures reported = 8,899. Multiple responses permitted per patient, 57 patients received both BCS and mastectomy.
b
Number of patients receiving BCS or mastectomy (not number of procedures performed). CMF = Cyclophosphamide, methotrexate and 5-fluorouracil; BCS = breast-conserving surgery.